CD20 positive

CD20-negative large B-cell lymphomas exhibit aggressive behavior and are ineligible for rituximab-containing therapy...In conclusion, CD79B and CD19 were variably expressed in CD20-negative large B-cell lymphomas, but lower in de novo DLBCL, and especially in plasmablastic lymphoma. Programmed cell death protein 1/programmed death-ligand one inhibitors may represent a treatment option.

P1/2, N=195, Active, not recruiting, Genmab | Recruiting --> Active, not recruiting | N=424 --> 195

P2, N=60, Recruiting, The Lymphoma Academic Research Organisation | Not yet recruiting --> Recruiting

Diffuse large B-cell lymphoma (DLBCL) can undergo stepwise immunophenotypic and molecular evolution over decades, progressing from a germinal Center B-cell-like (GCB)-like phenotype to an activated B-cell -like/non-GCB pattern (MUM1+, CD30+) and ultimately to an aggressive anaplastic variant.The cell-of-origin profile and its associated molecular features are not necessarily static; thus, therapeutic strategies for relapsed DLBCL should be tailored to the current disease state rather than relying on the signature at initial diagnosis.Longitudinal re-evaluation through repeat biopsies is imperative to capture the evolving landscape of the malignancy, ensuring that treatment selection is guided by the most recent pathological and molecular findings.

P2, N=58, Recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=20, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028

Strikingly, the addition of PD1 alone or the PD1 plus CTLA4 doublet to low-dose 211At-hCD20 significantly strengthened suppression of both tumors and increased mouse survival. Future translation of this synergistic combination of α-radiotherapy and immune checkpoint inhibition holds promise for the treatment of high-risk aggressive lymphomas, including cases with postinduction minimal residual disease or antigen loss after targeted therapies.

The avidity of both 68Ga- and 177Lu- cyclic pentapeptide radiotracers was noted in the mesenteric mass at the L4 level. Dosimetry study using 177Lu-cyclic pentapeptide indicated kidneys as the critical organ with max residence time of 5.39 h. Theragnostic complex of radiolabelled 68Ga/177Lu- cyclic pentapeptides have the potential to in-vivo target the CXCR4 receptor expression.

The patient was transferred to the hematology department to initiate chemotherapy with the R-CHOP regimen...Intestinal IVLBCL, a rare malignant lymphoma characterized by the selective proliferation of tumor cells within the lumen of small- to medium-sized blood vessels, represents a GI manifestation of IVLBCL. This case report describes a 78-year-old man who presented with vomiting and abdominal pain and was diagnosed with IVLBCL.

P1/2, N=90, Recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=150 --> 90

P=N/A, N=74, Not yet recruiting, The First Affiliated Hospital of the Air Force Medical University; The First Affiliated Hospital of the Air Force Medical University

P=N/A, N=40, Not yet recruiting, The Affiliated Hospital of Southwest Medical University; The Affiliated Hospital of Southwest Medical University